- Home
- APLM vs JVA Comparison
APLM vs JVA Comparison
Compare APLM & JVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- JVA
- Stock Information
- Founded
- APLM 2016
- JVA 1971
- Country
- APLM United States
- JVA United States
- Employees
- APLM N/A
- JVA N/A
- Industry
- APLM Blank Checks
- JVA Packaged Foods
- Sector
- APLM Finance
- JVA Consumer Staples
- Exchange
- APLM Nasdaq
- JVA Nasdaq
- Market Cap
- APLM 15.6M
- JVA N/A
- IPO Year
- APLM N/A
- JVA 2005
- Fundamental
- Price
- APLM $9.75
- JVA $3.68
- Analyst Decision
- APLM Strong Buy
- JVA
- Analyst Count
- APLM 2
- JVA 0
- Target Price
- APLM $425.00
- JVA N/A
- AVG Volume (30 Days)
- APLM 102.2K
- JVA 162.6K
- Earning Date
- APLM 02-15-2025
- JVA 02-07-2025
- Dividend Yield
- APLM N/A
- JVA N/A
- EPS Growth
- APLM N/A
- JVA N/A
- EPS
- APLM N/A
- JVA 0.20
- Revenue
- APLM $2,101,000.00
- JVA $76,111,698.00
- Revenue This Year
- APLM N/A
- JVA N/A
- Revenue Next Year
- APLM N/A
- JVA N/A
- P/E Ratio
- APLM N/A
- JVA $18.10
- Revenue Growth
- APLM 70.54
- JVA 17.27
- 52 Week Low
- APLM $6.50
- JVA $0.81
- 52 Week High
- APLM $105.00
- JVA $4.66
- Technical
- Relative Strength Index (RSI)
- APLM 50.39
- JVA 47.99
- Support Level
- APLM $7.23
- JVA $3.92
- Resistance Level
- APLM $8.88
- JVA $4.66
- Average True Range (ATR)
- APLM 1.37
- JVA 0.40
- MACD
- APLM 0.21
- JVA -0.07
- Stochastic Oscillator
- APLM 57.91
- JVA 22.22
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.